Clinical trial
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution…
NCT00315731 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00315731 |
|---|---|
| Title | A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma |
| Official title | A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular |
| Intervention type | Biological |
| Interventions | Follicular Lymphoma |
| Enrollment | 15 |
| Start date | Mar 31, 2003 |
| Primary completion | Dec 4, 2006 |
| Completion | Jun 30, 2013 |
| First posted | Apr 19, 2006 |
| Last update posted | Jul 11, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: